Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
National Cancer Institute (NCI)
Travera Inc
Nammi Therapeutics Inc
Canadian Cancer Trials Group
Exscientia AI Limited
Alliance for Clinical Trials in Oncology
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
NRG Oncology
Arcus Biosciences, Inc.
Memorial Sloan Kettering Cancer Center
Sotio Biotech Inc.
National Cancer Institute (NCI)
GlaxoSmithKline
AstraZeneca
Merck Sharp & Dohme LLC
Mayo Clinic
Roswell Park Cancer Institute
Hoffmann-La Roche
ViroMissile, Inc.
Duke University
Tizona Therapeutics, Inc
A2 Biotherapeutics Inc.
Poseida Therapeutics, Inc.
MacroGenics
City of Hope Medical Center
M.D. Anderson Cancer Center
Ocellaris Pharma, Inc.
Novartis
Mayo Clinic
NeoTX Therapeutics Ltd.
OncoHost Ltd.
Bolt Biotherapeutics, Inc.
Nanobiotix
ITM Oncologics GmbH
Actym Therapeutics, Inc.
Janux Therapeutics
Sichuan Baili Pharmaceutical Co., Ltd.
Scancell Ltd
A2 Biotherapeutics Inc.
Exelixis
Incyte Corporation
Jonsson Comprehensive Cancer Center
Xencor, Inc.
Numab Therapeutics AG
University of California, San Francisco
NuCana plc
A2 Biotherapeutics Inc.